Dihexa: Evidence, Claims and the Retracted Paper
Dihexa is sold on the strength of one number: that it is up to ten million times more potent than BDNF at building synapses. That number has a specific source, and the source has a problem — the paper it comes from was retracted in 2025. Anyone researching this compound deserves to know that before anything else, so this page leads with it.
What dihexa is
Angiotensin IV is a fragment of the renin-angiotensin system that turned out, unusually, to have procognitive effects in animal models. Its problem as a drug candidate is that the body degrades it almost immediately. Researchers at Washington State University built a series of metabolically stabilized analogs to get around this, and dihexa is the best known of them: modified at both ends to resist enzymatic breakdown, small enough to cross the blood-brain barrier, and orally active in rodents.
The 2013 paper introducing these analogs reported procognitive effects in rodent dementia models. That paper has not been retracted and remains the most solid published basis for interest in the compound. Note what it is: a rodent study.
What the evidence tiers actually look like
| Claim you will see | Evidence behind it | Status |
|---|---|---|
| Improves cognition | Rodent dementia models (McCoy 2013) | Animal only — never tested in a person |
| 10 million times more potent than BDNF | Cultured neuron synaptogenesis assay | Primary source retracted (2025) |
| Works through HGF/c-Met | Same retracted 2014 paper | Primary source retracted (2025) |
| Treats Alzheimer's or Parkinson's | Preclinical program only | No clinical trial published or registered |
| Safe for human use | None | No human safety data of any kind |
Why "more potent than BDNF" is not the claim it sounds like
Even setting the retraction aside, a potency ratio measured in cultured neurons answers a narrow question: how much of compound A versus compound B is needed to produce a given effect in that specific assay. It says nothing about whether the effect happens in a living brain, whether it produces measurable cognitive change, or whether it is safe. Potency and clinical benefit are different axes, and conflating them is how a cell-culture measurement becomes a marketing headline.
This is the same reasoning error covered on oursafety overview: a mechanism found in a dish is a hypothesis about people, not a finding about them.
The unresolved safety question
The proposed mechanism deserves attention precisely because of what it does. The HGF/c-Met system drives cell growth, migration and survival — the reason it is attractive for regenerating synapses is the same reason it is studied intensively in oncology, where c-Met activation is implicated in tumor growth and metastasis in several cancer types. No study has shown dihexa causes or accelerates cancer. No study has looked. With no human toxicology, no dose-finding work and no published safety package, "unknown" is the complete and accurate description of its risk profile.
What would change the picture
A registered clinical trial with published results; an independent replication of the synaptogenesis findings in a non-retracted paper; or a published toxicology package. None of these currently exists. We check ClinicalTrials.gov and PubMed when this page is reviewed, and this section will say something different when they do.
Research on Dihexa
3 records in our research database, classified by evidence type:
- AnimalThe development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseasesWright JW, Harding JW · Progress in Neurobiology, 2015
- AnimalThe procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system — RETRACTEDBenoist CC et al. · Journal of Pharmacology and Experimental Therapeutics, 2014
- AnimalEvaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agentsMcCoy AT et al. · Journal of Pharmacology and Experimental Therapeutics, 2013
Dihexa — research vial — American Peptides
Sold for laboratory research only. With no human data and no established dose, this is an unusually early-stage compound — batch identity documentation is the minimum, not a reassurance about the compound itself.
We may earn a commission if you buy through this link (at no extra cost to you). Sold for research purposes only.
Frequently asked questions
What is dihexa?
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small compound derived from angiotensin IV, developed at Washington State University as a candidate treatment for Alzheimer's and Parkinson's disease. It was designed to be metabolically stable and to cross the blood-brain barrier. All published work on it is preclinical.
Is dihexa really 10 million times more potent than BDNF?
That figure comes from a laboratory comparison of synaptogenic activity in cultured neurons — a potency ratio measured in a dish, not a measure of clinical effect. More importantly, the 2014 paper that is the usual source for this claim was formally retracted in 2025 after an expression of concern in 2021. A retracted paper is not a citable basis for anything.
Are there human studies on dihexa?
No published clinical trial of dihexa exists, and no trial appears in the ClinicalTrials.gov registry. Everything known about its effects comes from rodent and cell-culture work by a small number of research groups.
Is dihexa safe?
Nobody knows. There is no human safety data, no dose-finding study, and no toxicology package in the public literature. The mechanism proposed for it — activating the HGF/c-Met system, which drives cell growth and is implicated in several cancers — is a reason for caution rather than reassurance, and it has never been evaluated in people.
Is dihexa a peptide?
It is peptide-derived rather than a conventional peptide: a small modified tripeptide analog engineered for oral stability. That engineering is the point — angiotensin IV itself is broken down too quickly to be useful, and dihexa was built to survive.
Sources
- McCoy AT et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. Journal of Pharmacology and Experimental Therapeutics, 2013. PubMed
- Benoist CC et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. Journal of Pharmacology and Experimental Therapeutics, 2014;351(2):390–402. Retracted 2025 — original record · retraction notice
- Wright JW, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Progress in Neurobiology, 2015 — review by the originating group. PubMed
- Wright JW, Harding JW. The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease. Journal of Alzheimer's Disease, 2015. PubMed
- Absence of registered clinical trials verified against ClinicalTrials.gov and PubMed in August 2026.
Related guides
- Are peptides safe? Evidence tiers explained
- Peptide index: every compound we cover
- Research database: filter by evidence type
- Peptide reconstitution calculator